Work

Updated biomarker results from a phase 1/2 study of olaparib and radium-223 in men with metastatic castration-resistant prostate cancer (mCRPC) with bone metastases (COMRADE).

Year: 2022

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2022.40.6_suppl.119

Authors: Rana R. McKay, Wanling Xie, Archana Ajmera, Biren Saraiya, Mamta Parikh, Edmund Folefac, Adam C. Olson, Elisabeth I. Heath, Rahul Atul Parikh, S. Percy Ivy, Eliezer Mendel Van Allen, Neal Ian Lindeman, Geoffrey Shapiro

Institutions: University of California San Diego, Dana-Farber Cancer Institute, Moores Cancer Center, Rutgers Cancer Institute, UC Davis Comprehensive Cancer Center, The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, Duke Medical Center, Wayne State University, The Barbara Ann Karmanos Cancer Institute, University of Kansas Medical Center, National Cancer Institute, Brigham and Women's Hospital

Language: English

Topic: Prostate Cancer Treatment and Research

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4212915930

Cites:

Cited by: 2

Related to: 10